Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: Matching-adjusted indirect comparison analysis

被引：0
|
作者：
Gardini, A. Casadei [1 ]
Rimassa, L. [2 ,3 ]
Yoo, C. [4 ]
Lonardi, S. [5 ]
Cucchetti, A. [6 ]
机构：
[1] Osped San Raffaele, Milan, Italy
[2] Humanitas Univ, Pieve Emanuele, Italy
[3] IRCCS Humanitas Res Hosp, Rozzano, Italy
[4] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[5] Ist Oncol Veneto IRCCS, Med Oncol Unit 1, Dept Clin & Expt Oncol, Padua, Italy
[6] Univ Bologna, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-26
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [1] Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
    Andrea Casadei-Gardini
    Lorenza Rimassa
    Margherita Rimini
    Changhoon Yoo
    Baek-Yeol Ryoo
    Sara Lonardi
    Gianluca Masi
    Hyung-Don Kim
    Caterina Vivaldi
    Min-Hee Ryu
    Mario Domenico Rizzato
    Francesca Salani
    Yeonghak Bang
    Antonio Pellino
    Silvia Catanese
    Valentina Burgio
    Stefano Cascinu
    Alessandro Cucchetti
    [J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3665 - 3671
  • [2] Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
    Casadei-Gardini, Andrea
    Rimassa, Lorenza
    Rimini, Margherita
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Lonardi, Sara
    Masi, Gianluca
    Kim, Hyung-Don
    Vivaldi, Caterina
    Ryu, Min-Hee
    Rizzato, Mario Domenico
    Salani, Francesca
    Bang, Yeonghak
    Pellino, Antonio
    Catanese, Silvia
    Burgio, Valentina
    Cascinu, Stefano
    Cucchetti, Alessandro
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (12) : 3665 - 3671
  • [3] Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
    Merle, Philippe
    Kudo, Masatoshi
    Krotneva, Stanimira
    Ozgurdal, Kirhan
    Su, Yun
    Proskorovsky, Irina
    [J]. LIVER CANCER, 2023, 12 (02) : 145 - 155
  • [4] Matching-Adjusted Indirect Comparison of Cabozantinib (C) Versus Regorafenib (R) in Advanced Hepatocellular Carcinoma (HCC)
    Venerito, Morino
    Kelley, R. K.
    Mollon, P.
    Blanc, J. F.
    Daniele, B.
    Yau, T.
    Cheng, A. L.
    Valcheva, V.
    Azocar, A. Remiro
    Baio, G.
    Li, Y.
    Abou-Alfa, G. K.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [5] Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC).
    Proskorovsky, Irina
    Krotneva, Mira
    Ozgurdal, Kirhan
    Jaeger, Savina
    Su, Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA
    Roskell, N.
    Gregory, J.
    Wisniewski, T.
    Thompson, G. J.
    De la Cruz, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S17 - S18
  • [7] Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
    Trojan, Jorg
    Mollon, Patrick
    Daniele, Bruno
    Marteau, Florence
    Martin, Lidia
    Li, Yuxin
    Xu, Qing
    Piscaglia, Fabio
    Zaucha, Renata
    Sarker, Debashis
    Lim, Ho Yeong
    Venerito, Marino
    [J]. ADVANCES IN THERAPY, 2021, 38 (05) : 2472 - 2490
  • [8] Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
    Jörg Trojan
    Patrick Mollon
    Bruno Daniele
    Florence Marteau
    Lidia Martín
    Yuxin Li
    Qing Xu
    Fabio Piscaglia
    Renata Zaucha
    Debashis Sarker
    Ho Yeong Lim
    Marino Venerito
    [J]. Advances in Therapy, 2021, 38 : 2472 - 2490
  • [9] Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
    Tomonari, Tetsu
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Sogabe, Msasahiro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    [J]. JGH OPEN, 2020, 4 (06): : 1135 - 1139
  • [10] Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen L.
    Lim, Ho Yeong
    Baron, Ari D.
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas
    Lougheed, Julie C.
    Milwee, Steven
    El-Khoueiry, Anthony B.
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    [J]. ESMO OPEN, 2020, 5 (04) : 1 - 9
12345